Seizert Capital Partners’s Amgen AMGN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$6.8M Sell
19,337
-2,541
-12% -$906K 0.31% 54
2025
Q4
$7.16M Sell
21,878
-1,800
-8% -$571K 0.3% 55
2025
Q3
$6.68M Sell
23,678
-139,258
-85% -$40.4M 0.29% 58
2025
Q2
$45.5M Sell
162,936
-11,950
-7% -$3.39M 2% 21
2025
Q1
$54.5M Sell
174,886
-15,376
-8% -$4.54M 2.5% 10
2024
Q4
$49.6M Sell
190,262
-2,580
-1% -$765K 2.24% 13
2024
Q3
$62.1M Buy
192,842
+1,403
+0.7% +$459K 2.81% 4
2024
Q2
$59.8M Sell
191,439
-15,935
-8% -$4.68M 2.97% 5
2024
Q1
$59M Buy
207,374
+2,597
+1% +$760K 2.72% 7
2023
Q4
$59M Sell
204,777
-6,729
-3% -$1.83M 2.99% 6
2023
Q3
$56.8M Buy
211,506
+2,918
+1% +$728K 3.01% 3
2023
Q2
$46.3M Buy
208,588
+4,810
+2% +$1.12M 2.48% 9
2023
Q1
$49.3M Buy
203,778
+14,249
+8% +$3.5M 2.71% 7
2022
Q4
$49.8M Sell
189,529
-19,263
-9% -$5.16M 2.64% 5
2022
Q3
$47.1M Buy
208,792
+484
+0.2% +$117K 2.65% 5
2022
Q2
$50.7M Buy
208,308
+4,605
+2% +$1.13M 2.69% 4
2022
Q1
$49.3M Buy
203,703
+348
+0.2% +$80K 2.26% 10
2021
Q4
$45.7M Buy
203,355
+3,201
+2% +$676K 2.05% 16
2021
Q3
$42.6M Buy
200,154
+4,626
+2% +$1.06M 1.95% 18
2021
Q2
$47.7M Buy
195,528
+36,202
+23% +$8.91M 2.27% 11
2021
Q1
$39.6M Buy
159,326
+19,633
+14% +$4.68M 2.07% 14
2020
Q4
$32.1M Buy
139,693
+2,869
+2% +$661K 1.87% 17
2020
Q3
$34.8M Sell
136,824
-8,336
-6% -$2.07M 2.28% 10
2020
Q2
$34.2M Sell
145,160
-7,396
-5% -$1.69M 2.32% 13
2020
Q1
$30.9M Sell
152,556
-55,887
-27% -$12.2M 2.28% 14
2019
Q4
$50.2M Sell
208,443
-9,755
-4% -$2.15M 2.5% 10
2019
Q3
$42.2M Sell
218,198
-27,544
-11% -$5.29M 2.13% 14
2019
Q2
$45.3M Sell
245,742
-19,935
-8% -$3.57M 2.23% 12
2019
Q1
$50.5M Sell
265,677
-569
-0.2% -$109K 2.26% 11
2018
Q4
$51.8M Sell
266,246
-11,386
-4% -$2.22M 2.34% 10
2018
Q3
$57.5M Buy
277,632
+30,466
+12% +$6M 2.12% 11
2018
Q2
$42.1M Hold
247,166
1.53% 24
2018
Q1
$42.1M Buy
247,166
+3,596
+1% +$660K 1.53% 24
2017
Q4
$42.4M Buy
243,570
+1,506
+0.6% +$267K 1.52% 26
2017
Q3
$45.1M Sell
242,064
-16,538
-6% -$2.93M 1.66% 22
2017
Q2
$44.5M Buy
258,602
+2,478
+1% +$403K 1.61% 25
2017
Q1
$42M Buy
256,124
+3,098
+1% +$515K 1.49% 28
2016
Q4
$37M Sell
253,026
-5,052
-2% -$760K 1.31% 29
2016
Q3
$43M Sell
258,078
-29,339
-10% -$4.96M 1.6% 22
2016
Q2
$43.7M Sell
287,417
-42,309
-13% -$6.58M 1.66% 21
2016
Q1
$49.4M Buy
329,726
+5,679
+2% +$844K 1.68% 21
2015
Q4
$52.6M Sell
324,047
-12,112
-4% -$1.9M 1.64% 22
2015
Q3
$46.5M Sell
336,159
-24,397
-7% -$3.85M 1.41% 33
2015
Q2
$55.4M Buy
360,556
+5,081
+1% +$814K 1.41% 30
2015
Q1
$56.8M Sell
355,475
-66,909
-16% -$10.5M 1.43% 25
2014
Q4
$67.3M Sell
422,384
-111,992
-21% -$17.5M 1.42% 29
2014
Q3
$75.1M Sell
534,376
-1,133
-0.2% -$148K 1.5% 25
2014
Q2
$63.4M Buy
535,509
+172,961
+48% +$20M 1.26% 38
2014
Q1
$44.7M Sell
362,548
-31,135
-8% -$3.78M 1.05% 48
2013
Q4
$44.9M Sell
393,683
-42,611
-10% -$4.85M 1.06% 46
2013
Q3
$48.8M Sell
436,294
-177,296
-29% -$19.2M 1.33% 33
2013
Q2
$60.5M Buy
+613,590
New +$63.7M 1.65% 23

Other funds holding AMGN

Seizert Capital Partners's AMGN Position: Q1 2026 in Review

Seizert Capital Partners reduced its Amgen (AMGN) stake by 12% in Q1 2026, selling an estimated $906K and leaving 19,337 shares worth $6.8M. The position accounts for 0.31% of the portfolio, ranked #54.

Seizert Capital Partners first reported a position in AMGN in Q2 2013 and has held it in 52 quarters since. The position peaked at $75.1M in Q3 2014. 3,129 funds tracked by Wall St. Rank hold AMGN as of Q1 2026.

  • Seizert Capital Partners held 19,337 shares of Amgen worth $6.8M as of Q1 2026.
  • Seizert Capital Partners sold 2,541 Amgen shares in Q1 2026, an estimated $906K.
  • Amgen made up 0.31% of Seizert Capital Partners's portfolio in Q1 2026, its #54 holding.
  • Seizert Capital Partners first reported a position in Amgen in Q2 2013 and has held it in 52 quarters since.
  • Seizert Capital Partners's Amgen position peaked at $75.1M in Q3 2014.
  • 3,129 funds tracked by Wall St. Rank held Amgen as of Q1 2026.

Based on Seizert Capital Partners's 13F filing for Q1 2026, filed 7 May 2026.